Tammy Reynolds, MD
Obstetrics & Gynecology · Las Vegas, NVNPI 1316145733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.0% of the total. Reporting peaked in 2023 at $1,084 and has fallen 55.8% since, to $479 in 2025.
Across 254 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$694
- Daiichi Sankyo Inc.$569
- Mayne Pharma Commercial LLC$283
- Hologic Sales And Service, LLC$262
- Exeltis, USA Inc.$211
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,54095%
- Education$2385%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,147 |
| Astellas Pharma US Inc | 28 | $694 |
| Daiichi Sankyo Inc. | 34 | $569 |
| Mayne Pharma Commercial LLC | 12 | $283 |
| Hologic Sales And Service, LLC | 13 | $262 |
| Exeltis, USA Inc. | 12 | $211 |
| Pfizer | 9 | $172 |
| Gynesonics, Inc. | 1 | $139 |
| Therapeuticsmd, Inc. | 9 | $137 |
| Bayer | 7 | $119 |
| Sage Therapeutics, LLC | 7 | $109 |
| Novo Nordisk | 4 | $81 |
| Evofem Biosciences, Inc. | 3 | $65 |
| Avion Pharmaceuticals | 4 | $61 |
| Roche Diagnostics Corporation | 3 | $57 |
| Amgen | 3 | $53 |
| AMAG Pharmaceuticals, Inc. | 3 | $49 |
| Momentis Surgical Inc. | 1 | $49 |
| Minerva Surgical, Inc | 3 | $47 |
| Optumhealth Care Solutions, LLC | 1 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| BD | 2 | $40 |
| Duchesnay USA Incorporated | 2 | $40 |
| Boston Scientific | 2 | $36 |
| Pacira Pharmaceuticals Incorporated | 2 | $36 |
| Agile Therapeutics, Inc. | 2 | $28 |
| Organon | 2 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Teleflex LLC | 1 | $18 |
| Solventum Corporation | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Coopersurgical, Inc. | 1 | $17 |
| Millicent US Inc | 1 | $17 |
| Intuitive Surgical | 1 | $16 |
| Dysis Medical, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Microline Surgical Inc | 1 | $14 |
| Lupin Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,778 in reported general payments places this provider in the 80th percentile of 308 obstetrics & gynecology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 12 | $12,322 |
| MyrbetriqMirabegron | 16 | $6,992 |
| PremarinEstrogens, Conjugated | 11 | $3,609 |
| Estradiol | 62 | $1,890 |
| ProgesteroneProgesterone, Micronized | 22 | $501 |
| Medroxyprogesterone Acetate | 14 | $400 |
| Sumatriptan Succinate | 14 | $41 |
| Escitalopram Oxalate | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $694 | $6,99216 claims |
| PfizerPremarin | $172 | $3,60911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 obstetrics & gynecology providers in Nevada.
Other obstetrics & gynecology in Las Vegas
- Darin SwainstonLas Vegas$713K
- Christina KushnirLas Vegas$502K
- Lamarr TylerLas Vegas$170K
- Ralph VennartLas Vegas$144K
- Kenneth VolkerLas Vegas$126K
- Navkaran SinghLas Vegas$104K
- Sunwook KimLas Vegas$94K
- Luis Lopez BenitezLas Vegas$89K
- Linda TranLas Vegas$72K
- Raul Romero JosephLas Vegas$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.